



# Arisha Patel, MD, MBA

Precision Oncologist · Physician-Scientist · Founder and CEO, BioNurture and BioSynova

hello@arishapatelmd.com · arishapatelmd.com · linkedin.com/in/arishapatelmd

Physician-scientist and founder building precision oncology for the years before a diagnosis and the decades after treatment. Triple board-certified in Medical Oncology, Hematology, and Internal Medicine, with an MBA in Biomedical Entrepreneurship and AI in Healthcare from Carnegie Mellon. Former Senior Medical Director of Personalized Healthcare at Genentech, where she led medical strategy for a tumor-agnostic basket trial that supported two NCCN Category 2A recommendations. Founder and CEO of BioNurture, a concierge oncology and hematology practice, and BioSynova, the clinical intelligence company that holds its intellectual property and care-delivery architecture.

## Experience

---

### Founder and Chief Executive Officer, BioNurture

2022 to present

Founded and lead a physician-led concierge oncology and hematology practice built for risk stratification before diagnosis and longitudinal survivorship after treatment. Pairs board-certified specialist care with coordinated synthesis of labs, imaging, and biomarkers into one clinical plan. Designed a membership care model with defined stabilization, optimization, and graduation pathways and the coordinated diagnostics and specialty partnerships to support it.

### Founder and Chief Executive Officer, BioSynova

2022 to present

Founded the clinical intelligence and infrastructure company underlying BioNurture, holding the intellectual property, clinical decision support, and operational architecture for longitudinal care. Developing the Cancer Resilience Index, a longitudinal measure of cancer risk now in research validation, designed to scale precision oncology and hematology nationally under physician supervision.

### Senior Medical Director, Personalized Healthcare, Genentech, Inc. (Roche Group)

2019 to 2021

Medical Director for MyPathway (NCT02091141), a tumor-agnostic Phase 2a basket trial across molecularly targeted and immuno-oncology agents. Led medical strategy that supported two NCCN Category 2A recommendations for pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer and salivary gland tumors. Built external-control-arm strategy using real-world data and machine learning, and co-led biomarker-testing coverage and policy work.

### Adjunct Clinical Instructor, Oncology and Hematology, Stanford University School of Medicine

2020 to 2022

## Selected Credentials and Recognition

---

- Triple board-certified: Medical Oncology, Hematology, Internal Medicine (American Board of Internal Medicine)
- NIH T32 postdoctoral research fellow, predictive machine learning in high-risk populations
- Two NCCN Category 2A recommendations from the MyPathway program
- Oral Late-Breaking Abstract presenter, ASCO Annual Meeting (2021); presentations at AACR and ASH
- Published in The Lancet Oncology, Cancer Discovery, JCO Clinical Cancer Informatics, British Journal of Haematology, and Cancer
- Board Member, The Board of Medicine, 2022 to present

## Education

---

- MBA, Biomedical Entrepreneurship and AI in Healthcare, Carnegie Mellon University, Tepper School of Business
- MD, Chicago Medical School, Rosalind Franklin University of Medicine and Science
- Fellowship, Hematology-Oncology, UPMC Hillman Cancer Center (NCI-designated)
- Residency, Internal Medicine, University of Pittsburgh Medical Center
- MS, Healthcare Administration and Management; MS, Biological Sciences, Rosalind Franklin University
- BS, Biology, Southern Methodist University

## Expertise

---

Precision and molecular oncology · Tumor-agnostic, biomarker-driven therapy · AI and machine learning in oncology · Clinical decision support · Real-world data and external control arms · Care delivery and practice design · Hematology · Cancer prevention and survivorship · Clinical trial medical strategy · Biomarker coverage and policy

## Available For

---

Fractional Chief Medical Officer and Medical Director engagements · Scientific, clinical, and corporate boards · Investor diligence and investment counsel · Expert consultation and expert witness · Keynotes and executive conversations

*Engagements are confidential. Inquiries at arishapatelmd.com.*